Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
Primary liver cancer is a common kind of digestive cancers with high malignancy, causing 745,500 deaths each year. Hepatocellular carcinoma is the major pathological type of primary liver cancer. Traditional treatment methods for patients with hepatocellular carcinoma have shown poor efficacy in kil...
Saved in:
Main Authors: | Yingjun Xie, Yien Xiang, Jiyao Sheng, Dan Zhang, Xiaoxiao Yao, Yongsheng Yang, Xuewen Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2018/8740976 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives
by: Michael Karin, et al.
Published: (2025-02-01) -
New insights into N6-methyladenosine in hepatocellular carcinoma immunotherapy
by: Mengran Li, et al.
Published: (2025-01-01) -
Spatial heterogeneity of the hepatocellular carcinoma microenvironment determines the efficacy of immunotherapy
by: Minni Zhang, et al.
Published: (2025-01-01) -
Immunity revealed: Stratifying hepatocellular carcinoma for precision immunotherapy
by: Konstantinos Arvanitakis, et al.
Published: (2025-03-01) -
Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
by: Masaud Shah, et al.
Published: (2025-01-01)